FNP-223, previously known as ASN90, is a reversible and substrate-competitive O-GlcNAcase enzyme inhibitor. The oral investigational drug is expected to rapidly increase O-GlcNAcylated tau proteins, ...

Phathom gains FDA exclusivity for VOQUEZNA through 2032, boosting stock. DCF values shares at $14 with 43% upside potential. See more on PHAT stock here.

In this GEN webinar, Dave Lahr, PhD, Senior Director of Bioinformatics at Foghorn Therapeutics, discusses chromatin regulation and epigenetic mechanisms that shape transcriptional responses to ...

Objective To assess the non-inferiority of vonoprazan to lansoprazole for secondary prevention of non-steroidal anti-inflammatory drug (NSAID)-induced peptic ulcer (PU) and the safety of vonoprazan ...

Fermented-litchi polysaccharide (Lzp) has been demonstrated to enhance the production of exopolysaccharides (EPS) in Weissella confusa in our previous study. To elucidate the underlying mechanisms, ...